Echo IQ Teams with Mayo Clinic to Test AI Cardiac Risk Tool in Cancer Patients
Echo IQ has partnered with Mayo Clinic to assess its AI platform's ability to predict heart failure risk in patients undergoing cancer therapy, targeting the growing cardio-oncology sector.
- Research collaboration with Mayo Clinic on cardiac risk AI
- Study to evaluate AI using routine echocardiographic data
- Focus on cardio-oncology amid rising cancer survival rates
- Study completion and publication expected by mid-2027
- FDA clearance for heart failure indication still pending
Echo IQ Expands AI Platform into Cardio-Oncology
Echo IQ Limited (ASX:EIQ) has secured a research collaboration with the Mayo Clinic to evaluate its AI-driven cardiac risk stratification platform in cancer patients receiving therapy. The study aims to determine whether Echo IQ's technology can predict heart failure risk from standard echocardiographic data, potentially enabling earlier intervention in a patient group vulnerable to treatment-related cardiac complications.
Study Design and Clinical Importance
Conducted at Mayo Clinic Arizona under Dr Chadi Ayoub, the research will process de-identified echocardiographic scans within a secure environment, applying Echo IQ’s AI model to generate predictive risk scores for heart failure. This addresses a critical challenge in cardio-oncology, where rising cancer survival rates have brought long-term cardiovascular side effects into sharper focus. Early risk identification could inform clinical decisions before symptoms manifest, improving patient outcomes.
Market and Regulatory Landscape
The cardio-oncology sector is rapidly emerging due to increasing demand for managing cardiovascular risks linked to cancer treatments. Globally, over 20 million new cancer cases occur annually, many requiring cardiac monitoring. Echo IQ’s AI platform is already FDA-cleared for aortic stenosis, although its application for heart failure remains under regulatory review. The company anticipates study completion and peer-reviewed publication in the first half of 2027, which could support further regulatory and commercial progress.
Strategic Implications for Echo IQ
CEO Dustin Haines highlighted the collaboration as a strategic opportunity to validate the AI platform in a high-need clinical population. This extends Echo IQ’s reach beyond its current cardiovascular focus, potentially opening new avenues in oncology-related cardiac care. The partnership with Mayo Clinic also builds on Echo IQ’s prior engagements with the institution, including distribution agreements and clinical validation efforts for its heart failure diagnostic tools.
Bottom Line?
The Mayo Clinic collaboration could pivot Echo IQ’s AI platform into a fast-growing cardio-oncology niche, but regulatory clearance and study outcomes remain key hurdles.
Questions in the middle?
- Will the AI platform demonstrate sufficient predictive accuracy in the cardio-oncology setting to influence clinical practice?
- How might FDA clearance for heart failure indication impact Echo IQ’s commercial trajectory?
- Could this collaboration lead to broader adoption of AI-driven cardiac risk tools in oncology care pathways?
